REDUCED DOSE OF ORMELOXIFENE IN DYSFUNCITONAL UTERINE BLEEDING-SAFETY AND EFFECTIVENESS

K Suhasini, G.Vijaya Lakshmi, Y Padma, C Sabitha
In: Journal of Evolution of Medical and Dental Sciences · 2016 · vol. 5(14) , pp. 664–669 · doi:10.14260/jemds/2016/152 · W2615816105
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study evaluated the effectiveness and safety of a reduced dose of Ormeloxifene for managing dysfunctional uterine bleeding, aiming to provide a cost-effective long-term treatment option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To evaluate the effectiveness and safety of reduced dose of Ormeloxifene in the management of Dysfunctional Uterine Bleeding (DUB). Long term medical management for DUB, which is ideal and cost-effective is not yet available. Once it is available, it can revolutionise the management of DUB in developing countries. If Ormeloxifene is proved to be effective long-term at lower doses with minimal side effects, it can prevent the major number of blood transfusions and hysterectomies, which are common especially in the lower socioeconomic group of patients who cannot afford costly conservative measures.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (15)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK